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Biological quality control for
cardiopulmonary exercise testing in
multicenter clinical trials
Janos Porszasz1*, Susan Blonshine2, Robert Cao1, Heather A. Paden3, Richard Casaburi1 and Harry B. Rossiter1,4
Abstract
Background: Precision and accuracy assurance in cardiopulmonary exercise testing (CPET) facilitates multicenter
clinical trials by maximizing statistical power and minimizing participant risk. Current guidelines recommend quality
control that is largely based on precision at individual testing centers (minimizing test–retest variability). The aim of
this study was to establish a multicenter biological quality control (BioQC) method that considers both precision
and accuracy in CPET.
Methods: BioQC testing was 6-min treadmill walking at 20 W and 70 W (below the lactate threshold) with healthy
non-smoking laboratory staff (15 centers; ~16 months). Measurements were made twice within the initial 4 weeks
and quarterly thereafter. Quality control was based on: 1) within-center precision (coefficient of variation [CV] for
oxygen uptake [V̇O2], carbon dioxide output [V̇CO2], and minute ventilation [V̇E] within ±10 %); and 2) a criterion
that V̇O2 at 20 W and 70 W, and ΔV̇O2/ΔWR were each within ±10 % predicted. “Failed” BioQC tests (i.e., those outside
the predetermined criterion) prompted troubleshooting and repeated measurements. An additional retrospective
analysis, using a composite z-score combining both BioQC precision and accuracy of V̇O2 at 70 W and ΔV̇O2/ΔWR, was
compared with the other methods.
Results: Of 129 tests (5 to 8 per center), 98 (76 %) were accepted by within-center precision alone. Within-center CV
was <9 %, but between-center CV remained high (9.6 to 12.5 %). Only 43 (33 %) tests had all V̇O2 measurements within
the ±10 % predicted criterion. However, a composite z-score of 0.67 identified 67 (52 %) non-normal outlying tests,
exclusion of which coincided with the minimum CV for CPET variables.
Conclusions: Study-wide BioQC using a composite z-score can increase study-wide precision and accuracy, and optimize
the design and conduct of multicenter clinical trials involving CPET.
Trial registration: ClinicalTrials.gov identifier: NCT01072396; February 19, 2010.
Keywords: Calibration, Treadmill test, Pulmonary gas exchange, Z-score, Precision and accuracy
Background
Cardiopulmonary exercise testing (CPET) is a non-
invasive, sensitive test to evaluate cardiopulmonary (pa-
tho-) physiology. CPET assesses the physiological basis
of functional capacity and exercise intolerance, and plays
a valuable role in diagnosis and clinical decision-making
[1]. CPET is also used to test intervention efficacy, e.g.,
exercise training in cardiovascular disease [2, 3], pul-
monary rehabilitation [4–8], and bronchodilator therapy
in multicenter trials [9–11]. These applications require
strong agreement between consecutively performed
tests within and among investigative centers. However,
precision (reproducibility, or test–retest variability) and
accuracy (trueness) of CPET depend on interactions
among: testing equipment variability, calibration, and
maintenance; physiological factors; participants’ cooper-
ation, motivation, and effort during testing; and know-
ledge, skills, and training of laboratory personnel [12].
Most factors cannot be controlled by a simple system
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calibration, emphasizing the importance of standardization
and quality control (QC). Clinicians can rely on trial results
only if interpretation is not biased by measurement error
[12, 13]. Therefore, assurance of study-wide precision and
accuracy has a major impact on the design and conduct of
multicenter trials, by maximizing statistical discriminatory
power, and minimizing laboratory burden and partici-
pant risk.
The American Thoracic Society (ATS)/American
College of Chest Physicians (ACCP) [4], American
Heart Association [3], and European Respiratory Society
(ERS) [7, 12] have published CPET recommendations and
standards. These give “best practice” for calibration and
QC, and provide typical coefficients of variation (CV) for
physiological measurements. ATS/ACCP [4] recommends
a biological QC (BioQC) procedure [14] whereby a healthy
subject on a stable diet performs regular exercise tests
at work rates (WR) below the lactate threshold [12]. As
physiologic responses are typically highly reproducible
[3, 7, 14–17], the use of healthy individuals performing
BioQC can assure reproducibility of the integrated
CPET measurement system for patient testing within
and between testing centers [18]. Jones and Kane [19]
used cycle ergometers and subjects who travelled to
each participating center for testing, to demonstrate the
efficacy of BioQC to minimize the study-wide CV for
oxygen uptake (V̇O2; 5.6 %), carbon dioxide output
(V̇CO2; 8.4 %), and minute ventilation (V̇E; 8.2 %) by
excluding the least precise results. Similarly, while
Gagnon et al. [20] showed good agreement among five
testing centers for V̇O2,peak, this approach did not de-
termine the precision and accuracy of measured exer-
cise responses to a standardized protocol. Importantly,
the intraclass correlation coefficient at low WR was <0.7
[20], emphasizing the need for QC of the relationship
between mechanical and metabolic power output. Brawner
et al. [21] used a standardized treadmill protocol, where
quality assurance was accepted if at least two of three
exercise stages fell within a “target range” for V̇O2. Ra-
ther than assuring the precision and accuracy of the
individual mechanical–metabolic power coupling, the
basis of the acceptability criteria (the “target range”) in
Brawner et al. [21] was wide, in part due to differences
in weights of the volunteers used to develop the nor-
mative data.
In this study, we sought to establish new CPET BioQC
acceptability criteria that considered both precision and
accuracy of the mechanical–metabolic power coupling
during a standardized treadmill protocol, and which would
be suitable for quality assurance in multicenter studies.
We report the outcome of a precision-based approach
to CPET QC in a multicenter trial (ClinicalTrials.gov
identifier: NCT01072396) and propose new QC proce-
dures based on both precision and accuracy to minimize
variability in multicenter trials. The patient characterization
and treatment phases of the parent trial have been reported
[22, 23]. Some of the results of this QC study have been
previously reported in the form of an abstract [24].
Methods
Individuals involved in BioQC procedures
The primary independent Institutional Review Board (IRB),
Chesapeake Research Review, Inc. (Columbia, MD, USA)
approved the host trial protocol (NCT01072396) for five
sites, which could utilize the study’s central IRB, while the
remaining 10 participating centers obtained individual IRB/
Independent Ethics Committee (IEC) approval (for details
see Additional file 1: Table S1). The approved protocol in-
cluded detailed exercise BioQC procedures in an Exercise
and Quality Control Procedure Manual in accordance with
ATS/ACCP recommendations [4]. During the trial, de-
identified BioQC data from a non-smoking, healthy
member of the laboratory staff at each center were sub-
mitted to a central reader. These laboratory staff mem-
bers were required to fast and not consume caffeinated
drinks for at least 2 h prior to testing, and their age,
height, and weight (dressed, wearing shoes) were re-
corded. This manuscript describes an exempt retro-
spective study of this de-identified physiologic BioQC
data from NCT01072396.
Equipment used at the study centers
Details of the CPET equipment, software versions, flow
sensors, and treadmill details used in the study are
shown in Additional file 2: Table S2. The treadmills were
run from exercise software, with the exception of one
center, where the treadmill was manually adjusted from
its own controller using a preapproved procedure.
Manual of procedures
All centers selected to take part in the trial were pro-
vided with an Exercise and Quality Control Procedure
Manual, which detailed a standardized approach to ex-
ercise testing, calibration, and QC. The main objectives
of the manual were to: (1) provide information about the
available guidelines to promote QC; (2) standardize
technical procedures in CPET in order to minimize vari-
ation within and between participating centers; and (3)
outline and standardize specific procedures involved in
the clinical study.
Staff training, and equipment calibration and verification
Prior to enrolment of patients in the clinical trial, each par-
ticipating center was visited by a consultant (TechEd Con-
sultants, Inc., Mason, MI, USA) to evaluate and verify the
equipment acceptability, and to standardize all QC and test
procedures by providing specific training for staff. Training
included an initial submaximal incremental exercise test
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and a BioQC constant work rate test. Details on staff train-
ing, and equipment calibration and verification are pro-
vided in Additional file 3.
A participating laboratory was only released for patient
testing when all CPET technical and equipment per-
formance qualifying criteria were met.
BioQC procedures
CPET systems were calibrated according to manufac-
turer’s instructions immediately prior to BioQC testing
(see Additional file 3). All centers measured V̇O2, V̇CO2,
and V̇E breath-by-breath via a mouthpiece, and heart rate
from the electrocardiogram. The BioQC was a two-stage
constant work rate treadmill exercise test. The 18-min
protocol consisted of: 3 min of standing rest; 3 min of slow
walking (0.8 mph); and 6 min each at 20 W (1.0 mph) and
70 W (1.8 mph). Treadmill grades for each WR were cal-
culated based on participant’s clothed weight [25].
BioQC procedures were carried out at the on-site training
visit, within 4 weeks post-training to verify validity of re-
sults, and quarterly thereafter for the duration of the study.
Systems that required servicing (analyzer replacement, soft-
ware updates, etc.) underwent an out-of-schedule BioQC
test and patient testing was resumed only when the system
passed the QC criteria. A maintenance and troubleshooting
log was used to record all preventative maintenance activ-
ities, as well as faults and repairs (see Additional file 4).
Accuracy and precision of gas exchange and ventilation
measurements
The BioQC tests were analyzed at a central reading site.
Physiologic responses were submitted as 10-s bin aver-
ages. Steady-state V̇O2, V̇CO2, and V̇E values were calcu-
lated by averaging the last 3 min of exercise at 20 W
and 70 W. Acceptability of each BioQC test was estab-
lished by three methods: the central reader method, the
z-score method, and the criterion method.
Central reader method
During the multicenter trial, BioQC acceptability was
based upon within-center precision. A single central
reader compared a BioQC result with the initiation and
accumulated quarterly tests within each center. The BioQC
was accepted if V̇O2, V̇CO2, and V̇E were within ±10 % of
the initial value based on the expected normal variance
[26–29] and ATS/ACCP requirements [4]. This method
established precision over time (after an initial accuracy
check at the staff-training visit) [4]. A measurement not
meeting these criteria was repeated after troubleshooting
(see Additional file 4).
Z-score method
After trial completion, all BioQC results were assessed
en bloc to establish generalizable acceptability criteria.
Accuracy and precision of BioQC data were based on
“position” and “slope” of the linear relationship between
V̇O2 and WR [30], as predicted by the following [27]:
V
:
O2 ¼ ð5:8 weight½kgÞ þ 151þ ð10:1WÞ ð1Þ
Position was established from % predicted V̇O2 at 70 W
(V̇O2,70W) and slope from % predicted “functional gain” be-
tween 20 W and 70 W (V̇O2,slope) based on a ΔV̇O2/ΔWR
of 10.1 mL/min/W [26, 27], which has an established nor-
mal range of approximately ±10 % [28, 29]. Thus, accuracy
was established by deviation from the predicted value, and
precision from the standard deviation (SD) of all BioQC
tests. A composite z-score in which position and slope
were equally weighted was calculated:
z¼ ABS % predicted :VO2;70W−100
 
=SD % predicted
:
VO2;70W
 
=2
þ ABS % predicted :VO2;slope−100
 
=SD % predicted
:
VO2;slope
 
=2
ð2Þ
where SD is the standard deviation of % predicted for
each variable. The Shapiro–Wilk test on the population
of % predicted V̇O2,70W and V̇O2,slope measurements was
used to identify z-score values associated with a system-
atic departure from normality (W statistic P ≤ 0.05). As
the composite z-score criterion is based on % predicted
values of all available tests across all centers, it was used
to establish the minimum acceptability of both the pre-
cision and accuracy of CPET measurements.
Criterion method
Both acceptability methods (reader and z-score) were com-
pared with the application of a rigid criterion that no single
V̇O2 measurement (V̇O2,20W, V̇O2,70W, and V̇O2,slope)
should deviate by more than ±10 % from predicted. If any
one measurement’s deviation exceeded ±10 % predicted,
the test was deemed to have failed QC.
Statistical analyses
Mean and SD were used to calculate CV for variables
within and between centers. Departure from normality
was assessed by the Shapiro–Wilk test. For multiple com-
parisons in one-way analysis of variance (ANOVA), the
Student–Newman–Keuls test was used. Statistical signifi-
cance was accepted if P ≤ 0.05. All calculations and statis-
tical analyses were performed using MS Excel (Redmond,
WA, USA) and SigmaPlot 12 (Systat, San Jose, CA, USA).
Results
BioQC laboratory staff were males (n = 8; age 41.4 ±
11.4 years, weight 86.6 ± 17.3 kg, body mass index [BMI]
28.0 ± 4.3 kg/m2) and females (n = 7; age 41.4 ± 8.4 years,
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weight 61.2 ± 10.8 kg, BMI 23.7 ± 4.9 kg/m2). The num-
ber of BioQC tests per center varied from five to eight,
depending on the length of time the center was active in
the trial (16.3 ± 3.1 months [range 10 to 20 months]).
This resulted in a total of 129 BioQC tests performed
(6.5 ± 1.2 per center), with each center having between
10 and 28 non-repeated pairs of BioQC tests. Overall,
therefore, there were 523 unique paired differences of
BioQC tests, which were used to establish the distribu-
tion properties of the measurements.
Within-center variability – central reader method
The central reader method accepted 98 (76 %) BioQC
tests; 21 (24 %) initial tests required troubleshooting and
repetition to meet QC acceptability criteria. At three
centers, all tests were accepted. Four centers required
one repeat test, two required two repeats, and five re-
quired three or more repeats to bring measurements
within acceptable CV limits. Thus, across all centers, 31
repeated tests were necessary to bring BioQC measure-
ments within acceptable CV limits (for a study-wide
total of 129 tests). Further details on troubleshooting of
the CPET systems during the study are provided in
Additional file 4.
The within-center mean and variability of accepted
BioQC tests are given in Table 1. The most precise vari-
ables were V̇O2 at 70 W (CV = 5.8 %) and ΔV̇O2/ΔWR,
which averaged 10.6 ± 0.8 mL/min/W (CV = 5.8 %). The
least precise variable was V̇CO2 at 20 W (CV = 9.2 %).
The assumption that V̇O2 at 70 W was below each indi-
vidual’s lactate threshold was supported by attainment of
a steady-state within 6 min.
Multicenter precision and accuracy
Z-score method
Study wide “position” accuracy of CPET measurements in
the z-score method was assessed using V̇O2,70W because, of
the two steady-state V̇O2 measurements, V̇O2,70W showed
less variability. Systematic inclusion of non-normal
(outlying) BioQC measurements at V̇O2,70W occurred
above a z-score of 0.67, while non-normal measurements
of ΔV̇O2/ΔWR occurred above a z-score of 0.75 (Fig. 1).
Thus, using a critical z-score of 0.67, 62 (48 %) tests were
deemed acceptable. At z = 0.67, multicenter CV for
V̇O2,20W, V̇O 2,70W, and ΔV̇O2/ΔWR were 6.2 %, 4.7 %,
and 6.0 %, respectively (Table 2). Accuracy was not differ-
ent from the criterion method (see below), and close to
100 % predicted in all cases (Table 2). The z-score was the
only method for which final selected data for all V̇O2 vari-
ables were normally distributed (Table 2). Composite z =
0.67 coincided with the lowest CV for absolute measure-
ments in all three variables (Fig. 2a). Systematic increases
in V̇O2 measurement CV were observed at a z-score of
~0.9 (Fig. 2a) and CV exceeded ATS/ACCP guideline rec-
ommendations at a z-score of ~1.0 (Fig. 2b). The CV of %
predicted measurements increased with increasing z-
score, and z = 0.67 corresponded to a CV in all three vari-
ables less than ~6 % (Fig. 2b) incorporating ~50 % of tests
(Fig. 2c). Using the composite z-score, a greater number
of tests were excluded than using the central reader
method (Table 2). Additionally, there was only 53 % agree-
ment in test acceptability between the central reader and
composite z-score methods. Overall, precision and accur-
acy for V̇O2 measurements using composite z ≤ 0.67 was
greater than the central reader method and very similar to
the criterion method, despite substantially more tests than
the latter being deemed within acceptable limits.
Criterion method
When a criterion of ±10 % variability in all V̇O2 measure-
ments (% predicted V̇O2,20W, V̇O2,70W, and V̇O2,slope) was
applied, only 43 (33 %) tests were acceptable. The cri-
terion method resulted in greater precision (lower CV)
and accuracy compared with the central reader method,
but was not normally distributed in all variables (Table 2).
Optimizing precision using distribution analysis of
paired differences
Analysis of 523 paired differences for V̇O2, V̇CO2, and
V̇E is shown in Fig. 3. By including all tests, none of the
variables were well described by a Gaussian distribution
(Fig. 3, open circles). Whereas, for tests with composite
z ≤ 0.67, all gas exchange and ventilation measurements
(except V̇E at rest) were distributed normally (Fig. 3,
closed circles). A composite z-score based on V̇O2 meas-
urement alone was effective in also excluding tests with
outlying, non-normal measurements in V̇CO2 and V̇E.
In all CPET variables, a QC method based on V̇O2 preci-
sion and accuracy among all centers reduced data vari-
ability by ~60 % compared with using no QC method,
and by ~50 % compared with the central reader method.
Table 1 Within-center variability of gas exchange and ventilation
measurement during treadmill exercise. Measurements were made
at work rates of 20 W and 70 W in 98 reader-accepted biological
quality control tests
Variable Work rate (W) Mean ± SD Coefficient of
variation (%)
V̇O2 , L/min 20 0.73 ± 0.15 8.5
70 1.26 ± 0.17 5.8
V̇CO2, L/min 20 0.59 ± 0.12 9.2
70 1.10 ± 0.12 7.2
V̇E, L/min 20 18.5 ± 4.2 8.3
70 29.5 ± 4.2 6.3
ΔV̇O2/ΔWR, mL/min/W Δ50 10.6 ± 0.8 5.8
SD standard deviation, V̇O2 oxygen uptake, V̇CO2 carbon dioxide output, V̇E
minute ventilation, ΔV̇O2/ΔWR “functional gain” or the increase in V̇O2 per W
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Discussion
To our knowledge, this is the first study to establish
study-wide precision and accuracy for CPET measure-
ments in multicenter trials, based on normalcy of the
coupling between mechanical and metabolic power out-
put. We found: 1) the CV of CPET measurements was
reduced using the central reader assessment of BioQC
exercise tests to minimize within-center variability; 2) a
rigid application of a ±10 % predicted V̇O2 cut-off criter-
ion excluded 67 % of all measurements, some of which
were within the normal distribution of accurate tests; and
3) the application of a composite z-score to identify mea-
surements lying outside normal limits increased the preci-
sion and accuracy of multicenter trial CPET
measurements by ~50 %.
Efficacy of CPET QC based on within-center precision
Acceptance rate by the central reader method for all
BioQC tests was 76 %. The BioQC process identified
measurement errors in 12 of 15 centers before measure-
ments of study patients were made in the parent clinical
trial. In six centers, measurement error was resolved by
standard troubleshooting approaches, and required only
one or two additional BioQC tests to demonstrate reso-
lution. The central reader method excluded outlying
tests based on reproducibility, and effectively excluded
tests departing from normality. Analysis of all tests
showed non-normal distribution, whereas including only
tests accepted by the central reader assessment resulted
in a data set that was not significantly different from a
normal distribution (Table 2). The central reading
process reduced within-center CV for gas exchange and
ventilation measurements to within the range 5.8 to
Fig. 1 Effect of z-score on normality of oxygen uptake (V̇O2) meas-
urement distribution. Normalcy of biological quality control test
measurements selected on the basis of a composite z-score. Above
a critical z-score of 0.67, the W statistic drops dramatically and the
distribution of paired differences becomes non-normal for V̇O2
at 70 W
Table 2 Characteristics of variability of oxygen uptake (V̇O2) measurements during 129 biological quality control tests, using three
different quality control methods
Variable Work rate (W) Number
(% of all tests)
Mean ± SD
(% predicted)
Median
(% predicted)
Coefficient of variation (%) Normality (Shapiro–Wilk)
V̇O2 at 20 W
All tests 20 129 (100) 92.1 ± 12.2 93.5 14.3 Passed
Criteriona 20 43 (33) 96.1 ± 5.4 94.8 5.6 P < 0.001
Readerb 20 98 (76) 91.9 ± 11.5d 93.1 12.5 Passed
Composite z-scorec 20 62 (48) 95.8 ± 5.9 95.0 6.2 Passed
V̇O2 at 70 W
All tests 70 129 (100) 97.5 ± 11.0 97.7 11.3 Passed
Criteriona 70 43 (33) 98.4 ± 4.1 98.1 4.2 Passed
Readerb 70 98 (76) 97.6 ± 9.4 97.1 9.6 Passed
Composite z-scorec 70 62 (48) 99.0 ± 4.6 98.4 4.7 Passed
ΔV̇O2/ΔWR
All tests Δ50 129 (100) 105.7 ± 13.6 105.8 12.9 P = 0.006
Criteriona Δ50 43 (33) 102.0 ± 5.4 102.5 5.3 Passed
Readerb Δ50 98 (76) 106.3 ± 11.4 105.1 10.7 P < 0.001
Composite z-scorec Δ50 62 (48) 103.9 ± 6.2 104.3 6.0 Passed
SD standard deviation, V̇O2 oxygen uptake, V̇CO2 carbon dioxide output, V̇E minute ventilation, ΔV̇O2/ΔWR “functional gain” or the increase in V̇O2 per W
aCriterion method was based on V̇O2,20W, V̇O2,70W and V̇O2,slope being within ±10 % predicted
bReader method was based on V̇O2, V̇CO2, and V̇E within ±10 % of the initial value
cComposite z-score of 0.67, based on deviation of V̇O2,70W and V̇O2,slope from predicted, with knowledge of SD from all BioQC tests
dP < 0.05 Student–Newman–Keuls multiple comparison test within the V̇O2 at 20 W
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9.2 % (Table 1), which is within the range generally ac-
cepted for CPET studies [3, 4, 12, 31, 32].
Application of a central BioQC reader, therefore, pro-
vided a beneficial addition that reduced measurement
variability in the multicenter trial. However, while
within-center variability was below the upper limits rec-
ommended by ATS/ACCP [4] (~10 %), there remained
variability between different centers. The between-center
CV for gas exchange measurements of all centrally ac-
cepted BioQC tests ranged from 9.6 to 12.5 % (Table 2).
This residual between-center variability effectively less-
ened the benefit of the BioQC method, and weakened
the statistical power to demonstrate a given change in
CPET outcome measures in the parent clinical trial [23].
CPET QC based on study-wide precision and accuracy
To our knowledge, only one previous study attempted a
QC regimen based on both precision and accuracy [21].
However, the accuracy criterion used was wide (±25 %)
because the approach did not account for differences in
mechanical power output during treadmill walking at
given speed/grade combinations among individuals dif-
fering in weight. Therefore, to develop an approach to
CPET QC in multicenter trials that included study-wide
precision and accuracy in the coupling of mechanical to
metabolic power, we applied two different BioQC methods.
The first, a simple criterion approach, rigidly excluded
BioQC tests in which accuracy of any one V̇O2 measure-
ment (V̇O2,20W, V̇O2,70W, and V̇O2,slope) lay outside 90 to
110 % of the predicted value at the calculated power out-
put. This approach appears inherently sensible, in that
measurements outside this ±10 % range (roughly based on
guideline recommendations [4, 31, 32]) are considered as
outlying, and thus excluded. However, a limitation is
that a relatively small error in only one variable
causes a failing BioQC test, even if all other measure-
ments are within the tolerable limit. The very low ac-
ceptability rate of tests across the 15 centers (33 %)
makes application of this criterion impractical. Indeed,
seven study centers would have been completely ex-
cluded from the trial, despite reporting demonstrably
accurate measurements based on the retrospective
analysis of the normal distribution of the BioQC mea-
surements (Fig. 3). Thus, while the rigid criterion dra-
matically improved the CV of CPET measurements, it
excluded data that were within the normal distribu-
tion of measurement variability (e.g., Fig. 1, Table 2).
Therefore, we developed a method that allowed small
variability outside the 90 to 110 % range for predicted
V̇O2, but could successfully identify outlying, non-normal
measurements and reduce between-center measurement
CV. The composite z-score considered equally, the rela-
tive deviation from the mean of “position” (V̇O2,70W) and
“slope” (ΔV̇O2/ΔWR) of the highly predictable relation-
ship between V̇O2 and WR. By combining error distribu-
tion of these two variables, a small deviation from
predicted (i.e., between ~87 % and ~113 %) in one meas-
urement was allowed as long as the other was accurate.
We found this method able to strongly predict systematic
deviations in non-normal measurements above a compos-
ite z-score of 0.67 (based on SD of all tests; Fig. 1). In
addition, composite z-score of 0.67 coincided with local
minima in CV of absolute V̇O2 measurements (Fig. 2a)
and resulted in a study-wide CV of ~6 % (Fig. 2b).
Fig. 2 Effect of z = 0.67 cut-off on the CV and number of accepted CPETs. a Coefficient of variation (CV) of the absolute oxygen uptake (V̇O2) at 20 W,
70 W, and the increase in V̇O2 per W (ΔV̇O2/ΔWR), at different z-scores. b CV of % predicted V̇O2 at 20 W, 70 W, and ΔV̇O2/ΔWR, at different z-scores. c
% of acceptable tests (n = 129), at different z-scores. The shaded area is the approximate range of z-scores (0.67 to 0.9) over which absolute measure-
ment CV was minimized (based on panel a, and transposed into panels b and c). The critical z-score is the minimum value for which all measurements
are normally distributed. It is noted that the absolute CV (panel a) depends on both variability in measurements and differences in weight of individ-
uals performing the biological quality control tests (absolute V̇O2 at 20 W and 70 W treadmill walking is dependent on weight). Weight of individuals
did not significantly vary during the trial. Despite this, the absolute CV is useful to isolate the z-score range at which the minimum CV occurred (shaded
bar). The variability due to measurement differences among centers is better assessed using % predicted values (panel b)
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Using z = 0.67 we were able to identify that 52 % of
the BioQC tests lay outside the normal distribution of
V̇O2 measurements. While this approach excluded more
tests than the central reading method, this combined
precision- and accuracy-based method achieved three
main benefits. Firstly, it had a strong agreement with the
rigid criterion-based approach (84 % agreement between
methods). Secondly, it had a relatively high acceptance
rate (48 %) without compromising narrow measurement
CV compared with the criterion method (Table 2).
Lastly, it had a low CV of CPET measurements; ~50 %
lower CV than that compared with central precision-
based QC approaches that form the basis of guideline
recommendations. This latter point is of considerable
importance for the design and conduct of multicenter
clinical trials with CPET measurement outcomes. By ap-
plying a z-score-based BioQC method across all centers,
we suggest that measurement variability can be reduced
by ~50 %, providing an increase in statistical power to
detect changes in CPET measurements. Regular BioQC
tests are not onerous and, until a larger BioQC data
population is established, any CPET laboratory seeking
to implement a QC procedure may simply apply the z-
score criterion using equation 2, and the study-wide
population SD values established in this study (11.0 %
and 13.6 % for V̇O2,70W and V̇O2,slope, respectively).
While we found the optimal z-score at 0.67, based on
distribution normality, the CV of absolute V̇O2 measure-
ments remained close to the minimum up to a z-score
of ~0.90, corresponding to ~65 % of all tests and a CV
for % predicted below ATS/ACCP guidelines (which oc-
curred at z-score ~1.0) [4]. Further research is required
to determine more precisely the optimal z-score within
the range of ~0.67 to ~0.90 that balances requirements
Fig. 3 Distribution of relative frequencies of paired differences from zero. Differences from zero for oxygen uptake (V̇O2), carbon dioxide output
(V̇CO2), and minute ventilation (V̇E) at rest (a–c), 20 W (d–f), and 70 W (g–i). None of the variables show normal distribution when all tests are considered
(Shapiro–Wilk test, P< 0.001). Test selection based on z≤ 0.67 resulted in all data at each level of exercise (with the exception of V̇E at rest) being normally
distributed (Shapiro–Wilk test, P> 0.05)
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of normality, minimized CV and the number of accepted
tests to inform CPET studies. Nevertheless, while using
a combined z-score of 0.67 would minimize CPET meas-
urement variability, any power calculations for future
clinical trials should also account for the response
variability inherent in the clinical population studied.
Thus, the combined z-score approach maximizes stat-
istical discriminatory power within multicenter trials
and minimizes laboratory testing burden and study
participant risk.
Strategies to minimize measurement variability
We found a relatively high rate of measurement error
over 16 months. Importantly, 8 of 15 centers (53 %) re-
quired at least one additional validation procedure after
an initial failing BioQC test. Each failure triggered a
CPET-system troubleshooting process, which included
site technicians and central support to identify the error
source. Most required involvement of the system manu-
facturer and eventually led to major equipment service,
emphasizing the need for regular maintenance.
In addition, this justifies the recommendation for fre-
quent and rigorously evaluated QC methods in order to
prevent large unexplained variability in CPET measure-
ments. The BioQC process used here also identified
equipment error prior to equipment failure, and allowed
centers to address failing components of CPET systems
before trial-related measurements were scheduled. Over-
all, our results support the view that systematic BioQC
is needed to achieve satisfactorily accurate and precise
data in multicenter trials employing CPET.
Limitations
A potential limitation relates to the accurate estimation
of treadmill WR. External WR is calculated considering
a subject’s weight [33]; but does not account for the in-
ertia associated with body movements while walking
[25]. These inertial components increase with weight,
which may reduce the accuracy of calculated WR and
predicted V̇O2 value upon which BioQC is based. A
similar phenomenon occurs in cycle ergometry, where
V̇O2 is influenced by pedaling frequency. However, a
change in treadmill speed between 20 W and 70 W (1.0
mph to 1.8 mph) requires an obligatory cadence increase
and thus variable internal work; in cycling, cadence can
be effectively controlled [34, 35]. One solution would be
to recruit BioQC subjects who are similar in weight to
potential trial patients. Another solution would be to use
calculations for treadmill WR that incorporate kinetic
energy (mv2) instead of momentum (mv).
Another limitation is that we used an equation to pre-
dict metabolic rate that was originally developed for
cycle ergometry. However, within the speed range used
in this study, measured and predicted metabolic rates
show strong agreement [25]. V̇O2 prediction was based
on a ΔV̇O2/ΔWR of 10.1 mL/min/W [26, 27]. A range
of studies support this value, e.g., 10.2 ± 1.0 mL/min/W
[28] and 9.9 ± 0.7 mL/min/W [29], although it is recog-
nized that a greater value may be seen in endurance-
trained individuals [26]. While, in this study we found
that ΔV̇O2/ΔWR averaged 10.6 mL/min/W, this mean
was derived from only 15 individuals who performed the
BioQC and was within the normal range. We found that
post hoc adjustment of the target ΔV̇O2/ΔWR between
10.1 mL/min/W and 10.6 mL/min/W excluded only one
additional BioQC test and had no effect on the optimal
z-score range. Nevertheless, equations to better calculate
treadmill WR to improve accuracy of the ΔV̇O2/ΔWR
target, or using exercise modalities such as cycling where
WR can be better controlled, would likely further im-
prove precision and accuracy provided by the composite
z-score BioQC method.
The BioQC method relies on the attainment of steady-
state metabolic responses below the lactate threshold at
70 W. This may require verification by an additional
incremental exercise test for non-invasive lactate thresh-
old estimation, and/or the use of a lower WR for less
aerobically fit or smaller individuals.
The QC method assesses instrumental measurement
precision and accuracy (as opposed to physiologic vari-
ability) from submaximal steady-state CPET measure-
ments, because the variability of predicted values for
healthy participants is low within this domain. However,
clinical trials typically assess both submaximal and max-
imal values from CPET measurements. Therefore, the
instrumental measurement precision determined in this
study may not necessarily reflect the instrumental preci-
sion of peak measurements, where breathing frequency
is greater, and the response times of the gas analyzers
become increasingly important. Nevertheless, quality as-
surance of the integrated CPET measurement system link-
ing the mechanical and metabolic power output within
the submaximal domain should also contribute to im-
proving assurance of multicenter instrumental preci-
sion and accuracy of maximal CPET measurements.
Conclusions
A central precision-based QC procedure for multicenter
studies with CPET as an outcome, reduced measurement
variability within center, but was not sufficient to assure
between-center measurement accuracy. Thus, we estab-
lished the distribution of measurements linking mechanical
and metabolic power output during multicenter CPET
testing, and used this to develop a composite z-score-based
method to assess accuracy and precision of CPET mea-
surements. Based on 129 moderate intensity BioQC
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exercise tests in healthy laboratory staff across 15 centers
and 16 months, we found that a composite z-score of 0.67
was able to detect non-normal (outlying) CPET mea-
surements and trigger CPET system troubleshooting,
enabling a reduction of multicenter measurement vari-
ability by ~50 %. The measurement distribution and z-
score method established in this study may be applied
to future multicenter studies where CPET variables are
measured. Thus, a study-wide precision- and accuracy-
based QC process is required to optimize the design,
sample size, and conduct of multicenter clinical trials
involving CPET measurements.
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